Clinical Medicine: Psychiatry 2009:2
Background
Anxiety disorders affect 6%-19% of adults in the Western world every year 1,2 and are associated with substantial disability, reduced quality of life, reduced work capacity, and increased healthcare use. [3] [4] [5] [6] [7] [8] conditions of a clinical trial 20%-60% of patients will not respond to psychotherapy or anti-anxiety medications. [9] [10] [11] [12] [13] Up to one-half of patients with anxiety symptoms use complementary therapies, 14, 15 sometimes provided by their physicians.
Anthroposophic medicine (AM) is a complementary therapy system founded by Rudolf Steiner and Ita Wegman 16 and provided by specially trained physicians in 56 countries worldwide. AM acknowledges a spiritual-existential dimension in man, which is assumed to interact with psychological and somatic levels in health and disease. AM therapy for anxiety disorders aims to counteract constitutional vulnerability, stimulate salutogenetic self-healing capacities, and strengthen patient autonomy. [18] [19] [20] The AM approach differs from conventional treatment in the use of special therapies (eurythmy movement exercises, art therapy, rhythmical massage therapy) 19, 21 and special medications.
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Eurythmy therapy is an artistic exercise therapy involving cognitive, emotional and volitional elements. 22 In eurythmy therapy sessions the patients are instructed or the whole body. Eurythmy movements are related to the sounds of vowels and consonants, to music intervals or to affective gestures, e.g. sympathy-antipathy. Between therapy sessions the patients exercise eurythmy movements daily. In AM art therapy the patients engage in painting, drawing, clay modelling, music or speech exercises. Rhythmical massage techniques include lifting movements, rhythmically undulating gliding movements, and complex movement patterns like lemniscates. AM medications are prepared from plants, minerals, animals and from medication therapy is typological correspondences between pathophysiological processes in man and formative forces working in minerals, plants, and nature.
19,23 AM therapy is provided by physicians (counselling, AM medication) and non-medical therapists (art, rhythmical massage, and eurythmy therapy). For patients with anxiety disorders the physician will choose among the available AM therapy modalities in order to tailor the treatment to individual disease features and the patient's constitution. AM treatments can be administered alone or combined with conventional psychotherapy and/or anti-anxiety medications.
To date AM therapy for anxiety disorders has been evaluated in case reports. 18, 24, 25 Here we present a preplanned subgroup analysis of patients with anxiety disorders from a prospective cohort study of AM therapy.
26

Methods
Study design and objective
This is a prospective two-year cohort study in a real-world medical setting. The study was initiated by a health insurance company as part of a research project on the effectiveness, costs, and safety of AM therapies in outpatients with chronic disease (Anthroposophic Medicine Outcomes Study, AMOS).
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The present pre-planned analysis concerned the subgroup of adult patients with anxiety disorders. therapy for this indication, the primary objective was to describe AM therapy for anxiety disorders (spectrum of anxiety indications and of AM therapy modalities used for them, extent of combination with conventional anti-anxiety therapy) as well as outcome of anxiety symptoms under AM treatment. Further research questions addressed quality of life, use of health services, adverse reactions, and therapy satisfaction.
Setting, participants, and therapy
for Anthroposophical Medicine in Germany and clinic were invited to participate in the AMOS study. 3a. AM-related consultation of at least 30 minutes followed by new prescription of AM medication, or 3b. new referral to AM therapy (art, eurythmy or rhythmical massage).
The main indication for AM therapy is depression
AMOS patients with anxiety symptoms but with depression as main treatment indication were analysed separately).
inclusion criteria No 3) for the anxiety disorder.
The physicians' diagnostic assessment of anxiety disorders was assisted by brief written clinical descriptions of the ICD-10 diagnoses F40
F41.1 Generalized anxiety disorder (GAD), F42 Obsessive-compulsive disorder, and F43.1 treated according to the physician's discretion. AM therapy was evaluated as a whole system.
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Clinical outcomes
Anxiety Severity, assessed on numerical rating scales from 0 ("not present") to 10 ("worst possible"), at six-month follow-up. Anxiety symptoms were also assessed by the Self-Rating Anxiety Scale, German version (SAS, 0-100). 29, 30 A patient self-report instrument was chosen for logistical reasons, and to avoid potential observation bias from physicians with an interest in AM having favorable outcomes. The SAS was selected among four self-report instruments available in the German language and recommended for clinical anxiety research 31 (reasons for discarding   32   Inventory  33 because it reportedly measures panic  34 State-Trait  Anxiety Inventory 30 because of the perceived lower utility of the "state" items for the present longitudinal study).
Depressive symptoms were assessed by the Center for Epidemiological Studies Depression Scale, German version . 35, 36 Symptom Score, the severity of one to six most relevant symptoms present at baseline, was assessed by patients on numerical rating scales from 0 ("not present") to 10 ("worst possible"). Quality of life was assessed by the SF-36 Health Survey Component summary measures, eight scales, Health Change item).
SAS was documented by patients enrolled after March 2001. CES-D was documented at baseline by all patients and documented during follow-up rated Anxiety Severity was documented after 0 and 6 months, while all other clinical outcomes were documented after 0, 3, 6, 12, 18 , and 24 months.
Other outcomes
Therapy outcome rating (0-10), satisfaction with therapy (0-10) and therapy effectiveness rating ("very effective, "effective", "less effective", "ineffective" or "not evaluable") were documented by the patients after 6 and 12 months.
Adverse reactions to medications or therapies were documented by the patients after 6, 12, 18 and 24 months and by the physicians after 6 months. The documentation included cause, intensity (mild /moderate/severe no/some/complete impairment of normal daily activities), and therapy withdrawal because of adverse reactions. Serious adverse events (death, life-threatening condition, acute in-patient hospitalization, new disease or accident causing permanent disability, congenital anomaly, new malignancy) were documented by the physicians throughout the study.
Use of adjunctive therapies and health services in the pre-study year was documented at study after six and 12 months, and use in the second study year was documented after 18 and 24 months. The (any physician or dentist, psychiatrists), diagnostic imaging (x-rays, computer tomography, magnetic resonance imaging, scintigrams), non-AM medications, physiotherapy, psychotherapy, inpatient hospital and rehabilitation treatment, surgery, and sick leave. Use of psychotherapy and conventional anti-anxiety medication (Anatomical Therapeutic N05B Anxiolytics, N05C Hypnotics and sedatives, N06 Antidepressants) in months 0-6 was analysed had at least six psychotherapy sessions or used antianxiety medication for at least one day per month.
Data collection
All data were documented with questionnaires all other items were documented by the patients, unless otherwise stated. The patient responses were not made available to the physicians. The physicians 60 Euro) per included and fully documented patient, while the patients received no compensation.
The data were entered twice by two different persons into Microsoft ® were compared and discrepancies resolved by checking with the original data.
Quality assurance, adherence to regulations
The study was approved by the Ethics Committee of the Faculty of Medicine Charité, Humboldt University Berlin, and was conducted according to the Helsinki Declaration and largely following the informed consent was obtained from all patients before enrolment.
Data analysis
The data analysis was performed on all patients ® 14. Three pre-planned sensitivity analyses (SA1-SA3) attrition, natural recovery, and conventional anti-anxiety therapies on the 0-6-month outcome of physician-and patient-rated Anxiety Severity. SA1 months were replaced with the last value carried forward. SA2 concerned natural recovery, which was assumed to be unlikely in patients with disease 41 The sample was restricted to patients with disease duration of at least 12 months prior to study enrolment. SA3 concerned the effects of conventional anti-anxiety therapies (see Other Outcomes, above, for details). The sample was restricted to patients not using conventional antievaluable diagnostic groups and AM therapy modality groups.
Results
Participating physicians and therapists
The patients were enrolled by 29 physicians with four psychiatrists, two internists, and two gynaecologists).
without study patients (n differences were found regarding gender (48.3% vs. 60.3% males), age (48.5 of years in practice (19.9 8.1 vs. 19.2 9.1), and the proportion of physicians working in primary care (82.8% vs. 86.2%).
The patients were treated by 36 different AM therapists (eurythmy, art, rhythmical massage).
without study patients (n differences were found regarding gender (86.1% vs. 80.8% women), age (mean 50.1 9.6 vs. 50.2 9.4 years) or the number of years since therapist Patient recruitment and follow-up anxiety disorders were screened for inclusion. Of and were included in the analysis. Eleven patients 1). The remaining nine patients were potentially eligible but not included for the following 4), physician's baseline documentation incomplete (n 3), patients' and physicians' baseline questionnaire dated 30 days apart (n 1), administrative reasons (n 1). Included patients (n 64) and potentially eligible but not included patients (n 9) did not of anxiety disorder or evaluable baseline scores (physician and patient-rated Anxiety Severity, Symptom Score).
50/64) were enrolled by general practitioners, 13% (n 8) by psychiatrists, 6% (n 4) by internists, and 3% (n 2) by gynaecologists. The physicians' settings were primary care practices (84% of patients, n 54/64), referral practice (14%, n 9), and outpatient clinics (2%, n 1). Each physician enrolled 1-2 patients (69%, n 20/29 physicians), 3-4 patients (21%, n 6), or 5-6 patients (10%, n 3).
The last patient follow-up ensued on 21 November at least one follow-up questionnaire. The patients were administered a total of 320 follow-up returned. Follow-up rates were 88% (n 56/64), 24 months, respectively. Respondents (n 50) and non-respondents (n 14) of the six-month follow-up questionnaire did not differ significantly regarding age, gender, disease duration or baseline parameters (physician-and patient-rated Anxiety Severity, SAS, Symptom Score). Corresponding dropout analysis for the 24-month follow also respondents (n 51) and non-respondents (n 13). The physician six-month follow-up documentation was available for 94% (60/64) of patients.
Baseline characteristics
The patients were recruited from 9 of 16 German federal states. Age groups were 19-29 years (16%, n 10/64), 30-49 years (58%, n of 42.3 11.4 years (range 19-68 years). A total of 86% (n 55/64) of the patients were women. Compared with the German population, patients had higher educational and occupational levels and were less frequently regular smokers, daily alcohol consumers, and overweight. Socio-demographic status was similar to the population regarding unemployment, severe disability status, sports activities, and the proportion of patients living alone and less favourable for work disability pension and sick-leave (Table 1) . A total of 36% (n 23/64) of patients had more than one anxiety diagnosis, while 55% (n 35/64) had more than one mental diagnosis (ICD-10 F00-F99). Most frequent anxiety diagnoses were GAD (44% of patients) and panic disorder (39%) ( Table 2 ). Median duration of the anxiety disorder was 4.5 years (interquartile range [IQR] 1.0-20.0 years, range 6 weeks to 40 years, mean 9.5 10.4 years).
A current comorbid non-anxiety disease was present in 81% (52/64) of patients, with a median of 2 (IQR 1-3) comorbid diseases per patient. Most were musculoskeletal, gastrointestinal and circulatory diseases (Table 2) . Most common comorbid nonanxiety mental disorders (ICD-10 three-digit codes) were F32 Depressive episode (8% of patients, n 5/64) and F48 Other neurotic disorder (3%, n 2). 
Therapy
At study enrolment, the duration of the consultation with the AM physician was 30 min in 53% (n 34/64) of patients, 30-44 min in 23% (n 15), 45-59 min in 5% (n 3), and 60 min in 19% (n 12). At enrolment 9% (n 3a (AM-related consultation of 30 minutes followed by new prescription of AM medication), 80% (n to AM eurythmy/art/massage therapy), and 11% (n 58 patients referred to AM eurythmy/art/massage therapy, 81% (n 3% (n 2) did not have AM therapy, and for 16% (n 9) the AM therapy documentation is incomplete. AM therapies used were eurythmy therapy (n 26 patients), rhythmical massage therapy (n 2), and art therapy (n 19) with the therapy modalities painting/ drawing/clay (n 13), speech exercises (n 4), and music (n 2). The AM therapy started median 5 (IQR 0-36) days after enrolment. Median therapy duration days), median number of therapy sessions was 12 (IQR 10-19, mean 15.1 8.2 sessions). During the 24-month follow-up, 56% (n 36/64) of patients used AM medications for anxiety or other indications.
The use of adjunctive therapies, health services, and sick leave was compared between the pre-study of psychotherapy sessions increased from average 14.3 sessions in the pre-study year to 12.1 0.026), and the number of inpatient rehabilitation days decreased from 3.8 12.4 days in the pre-study year to 0.0 0.0 days in the second year (p 0.024). The number of evaluable patients receiving inpatient rehabilitation was n 8/64 in the pre-study year, n The use of psychotherapy and conventional anti-anxiety medications in months 0-6 was analysed separately. A total of 33% (n patients had psychotherapy, 24% (n 12/51) used conventional anti-anxiety medications (see Methods 28/51) used neither psychotherapy nor anti-anxiety medications.
Clinical outcomes
All clinical outcomes were improved from baseline at all subsequent follow-ups (Figs. 1-5 ). For 12 of the 16 outcomes (physician-and patient-rated Anxiety Severity, SAS, CES-D, Symptom Score, and seven SF-36 scores) all improvements from baseline At six-month follow-up an improvement of 50% (n 25/44) of evaluable patients for patient rating and in 58% (n sizes for the 0-6-month comparison were large for nine outcomes (physician-and patient-rated Anxiety Severity, Symptom Score, SAS, CES-D, and four SF-36 scores), medium for one outcome, and small for six outcomes (Table 2) . Subgroup analyses showed similar improvement in evaluable diagnostic groups (GAD, panic disorder) and therapy modality groups (eurythmy therapy, AM art therapy) (Table 3) . We performed three sensitivity analyses of the 0-6-month outcome of physician-and patient-rated for further description). For physician rating, the individual analyses resulted in a reduction of the average 0-6 month improvement of maximum 11% (3.60 3.22 points). Combining all three analyses, the improvement was reduced by 12% (3.60 analyses resulted in a reduction of the improvement of maximum 14% (3.50 3.00 points). Combining all three analyses, the improvement was increased by 3% (3.50 3.59 points).
Self-rating Anxiety Scale
Other outcomes
At six-month follow-up, patients' average therapy outcome rating (numeric scale from 0 "no help at all" to 10 "helped very well") was 6.82 2.65. The patients' effectiveness rating of eurythmy, art or rhythmical massage therapy was positive ("very effective" or had started therapy, and negative ("less effective", "ineffective" or "not evaluable") in 14%. The ratings of therapy outcome, satisfaction, and effectiveness follow-up.
The frequency of reported adverse drug reactions was 14% (n 5 of 36 users) for AM medications and 14% (n Adverse drug reactions of severe intensity were 3, 3), while medication was stopped due to reported adverse reactions in 5, non-AM 3). Adverse reactions from nonmedication therapies were reported in four patients 1, Dorn
One patient was acutely hospitalized for 34 days for panic disorder, and one patient died from Acquired events were related to any therapy or medication.
Discussion
treatment for anxiety disorders. We aimed to obtain information on AM therapy for this indication under routine outpatient conditions in Germany and studied adults starting AM therapy for anxiety disorders. Most frequent anxiety diagnoses were GAD, panic disorder, and phobic disorders. Two-third of patients engaged conventional anti-anxiety medications. Under AM anxiety symptoms, other symptoms, and quality of life were observed. Strengths of this study include a detailed assessment of the therapy setting and therapy-related factors, a patients in Germany participated, the participating AM physicians and therapists resembled all eligible physicians and therapists with respect to sociodemographic characteristics, and 88% of screened and eligible patients were enrolled. These features suggest that the study to a high degree mirrors contemporary AM practice.
Because the frequency of individual anxiety diagnoses in AM outpatient care was largely unknown prior to the study, we included patients with a range of anxiety diagnoses. Also, to mirror clinical practice, where the selection of AM therapy options will vary according to individual features, we assessed AM as a whole system. 28 Supplementary subgroup analyses were possible and showed similar improvements in patients with GAD and panic disorder, and in patients receiving eurythmy therapy and AM art therapy. However, the sample size for other anxiety diagnoses and other AM therapy modality subgroups (medical, rhythmical massage) did not allow for subgroup analysis. Diagnosis, therapy modality, and other predictors of clinical outcome will also be addressed in a multivariate analysis of a larger dataset from the AMOS study (submitted for publication).
To accommodate the study documentation to any anxiety disorder, clinical outcomes did not include 31 while the SAS, a recommended instrument for GAD, 31 was only documented in a subset of patients.
Since the study had a long recruitment period, the study physicians were not able to participate throughout the period and to screen and enrol all a different subset of patients from the AMOS project (patients referred to AM therapies for any chronic indication and enrolled before 1 April 2001), it was estimated that physicians enrolled every fourth eligible patient. This selection could bias results if physicians were able to predict therapy response and if they preferentially screened and enrolled such patients for whom they expected a particularly favourable outcome. In this case one would expect the degree of selection ( the proportion of eligible vs. enrolled patients) to correlate positively with clinical outcomes. That was not the case, the correlation was almost zero ( 0.04). This analysis does not suggest that physicians' screening of eligible patients was affected by selection bias.
A limitation of the study is the absence of a comparison group receiving conventional treatment or no therapy. Accordingly, for the observed improvements one has to consider several other causes apart from the AM treatment. We therefore conducted a sensitivity analysis of physician-and patient-rated bias, natural recovery, and adjunctive therapies. These three factors together explained up till 12% of the 0-6 month improvement. According to a previous analysis from this research program, 41 regression to self-selection to therapy and study inclusion at symptom peaks explained up till 0.43 points (12%) of the improvement of an outcome corresponding to physician-rated Anxiety Severity in this analysis. Because 16 clinical outcomes were analysed with a total of 20 comparisons at six-month follow-up (Table 2) , the issue of multiple hypothesis-testing arises. 38 However, 18 of the 20 comparisons showed significant improvements and 14 comparisons had p-values 0.001. of anxiety disorders in AM settings. The female/ male ratio in this predominantly primary care sample (6.1/1.0) was higher than in German primary care patients with GAD (2.1/1.0) 43 or in German population samples with GAD (2.1/1.0) 44 or any anxiety disorder (2.2/1.0). 45 The higher proportion of women in this sample is in accordance with other studies of AM patients with chronic disease. more likely than men to engage in creative therapies such as AM art therapy and eurythmy therapy. Most frequent diagnoses were GAD, panic disorders, and phobic disorders, which is in accordance with data from German primary care. 48 The proportion of patients with more than one mental diagnosis (55%) was similar to the proportion among adults with anxiety disorders in the German population (62%). 45 However, these diagnostic comparisons should be treated with caution, since the diagnosis of mental disorders in our study was based on physicians' clinical diagnosis and not on a criteria-based assessment, apart from brief clinical descriptors of anxiety diagnoses. This feature may have lead to an underestimation of comorbid mental diagnoses in our study, as suggested by the low frequency of a physician's diagnosis of depression (8% of patients) compared to the high proportion of patients with clinically relevant depressive Baseline anxiety symptom severity, assessed by the SAS, was one-half to one standard deviation higher than baseline scores in clinical trials of anxiety patients from German primary care. 49, 50 Mental quality of life at baseline, assessed with the SF-36 Mental Component summary (28 points in all patients, 29 points in patients with GAD), was one-third standard deviation worse than in German adults with GAD. 44 Other anxiety-related baseline data such as number of anxiety episodes, recent crises or psychiatric inpatient hospitalizations were not documented and can therefore not be compared to other studies. The proportion of responders at six-month follow-up (patients with 50%
responder rates in trials of anti-anxiety medications or psychotherapy.
9,10,13
of AM therapies on anxiety in cancer patients. 51, 52 improvement of patients with anxiety disorders under AM treatment.
patients had no standard therapy (psychotherapy, anti-anxiety medication). Some patients with anxiety other patients discontinue standard therapies due to adverse reactions or reject them because they are passive (medication) or can be felt as intrusive or too verbal (psychotherapy). In this context, the AM non-verbal and artistic exercising therapies offer a different approach or even a bridge to opening up communication on a verbal level.
19
Conclusions
In this study, adults with anxiety disorders under AM treatment had long-term reduction of symptoms and improvement of quality of life. Improvements were similar in patients not using anti-anxiety medications or psychotherapy. Although the pre-post design of the present study does not allow for conclusions about AM therapies may be useful in the long-term care of patients with anxiety disorders. 
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